Our previous reports also showed that AAA patients treated with simvastatin have lower oxidative stress and reduced NF-κB and ERK1/2 signaling pathways [19, 20], thereby supporting the antioxidative role of simvastatin. Here, NFKB1 is linked to triple-A syndrome.